Overview
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
Eligibility
Inclusion Criteria:
- Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation
- Participants treated with tazemetostat
Exclusion Criteria:
- Participants with a history of hypersensitivity to any ingredient of Tazverik